Tag: parkinson’s disease

Prevail Therapeutics shares were on the rise on Monday after Wall Street learned that the Food & Drug Administration had granted fast track designation for PR001 for the treatment of Parkinson’s disease patients with a GBA1 mutation. Parkinson’s disease is a chronic, progressive neurodegenerative disorder that affects up to one million people in the United … Continue reading “The FDA Has Granted Prevail’s Parkinson’s Treatment Fast Track Designation”